Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction

Donghua Xie, Brian H. Annex, Craig F. Donatucci

Research output: Contribution to journalReview article

Abstract

The past decade has seen an explosion of new information on the physiology of penile erection, and pathophysiology of erectile dysfunction (ED). Hypercholesterolemia is a chronic condition that can lead to degeneration in the vasculature bed and can result in ED if the penile vasculature is involved. Angiogenesis is the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth to treat disorders of inadequate tissue perfusion, such as coronary artery disease and ED. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future. Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm for the treatment of ischemic heart and/or peripheral vascular disease, though clinical studies have not achieved similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, novel therapies which target multiple different angiogenic pathways are also being developed and tested. The penis is a convenient tissue target for gene therapy because of its external location and accessibility, the ubiquity of endothelial lined spaces, and low level of blood flow, especially in the flaccid state. Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the development of growth factors for hypercholesterolemic ED, the use of various growth factors for ED therapy, their routes of delivery, and the results in animal studies.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalAsian journal of andrology
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Erectile Dysfunction
Intercellular Signaling Peptides and Proteins
Blood Vessels
Therapeutics
Penile Erection
Peripheral Vascular Diseases
Explosions
Penis
Growth
Hypercholesterolemia
Genetic Therapy
Coronary Artery Disease
Perfusion
Cytokines

Keywords

  • Angiogenic growth factors
  • Erectile dysfunction
  • Hypercholesterolemia
  • Nitric oxide synthase

ASJC Scopus subject areas

  • Urology

Cite this

Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction. / Xie, Donghua; Annex, Brian H.; Donatucci, Craig F.

In: Asian journal of andrology, Vol. 10, No. 1, 01.01.2008, p. 23-27.

Research output: Contribution to journalReview article

Xie, Donghua ; Annex, Brian H. ; Donatucci, Craig F. / Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction. In: Asian journal of andrology. 2008 ; Vol. 10, No. 1. pp. 23-27.
@article{d478c196627441b2882789e630e1a91e,
title = "Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction",
abstract = "The past decade has seen an explosion of new information on the physiology of penile erection, and pathophysiology of erectile dysfunction (ED). Hypercholesterolemia is a chronic condition that can lead to degeneration in the vasculature bed and can result in ED if the penile vasculature is involved. Angiogenesis is the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth to treat disorders of inadequate tissue perfusion, such as coronary artery disease and ED. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future. Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm for the treatment of ischemic heart and/or peripheral vascular disease, though clinical studies have not achieved similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, novel therapies which target multiple different angiogenic pathways are also being developed and tested. The penis is a convenient tissue target for gene therapy because of its external location and accessibility, the ubiquity of endothelial lined spaces, and low level of blood flow, especially in the flaccid state. Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the development of growth factors for hypercholesterolemic ED, the use of various growth factors for ED therapy, their routes of delivery, and the results in animal studies.",
keywords = "Angiogenic growth factors, Erectile dysfunction, Hypercholesterolemia, Nitric oxide synthase",
author = "Donghua Xie and Annex, {Brian H.} and Donatucci, {Craig F.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1745-7262.2008.00372.x",
language = "English (US)",
volume = "10",
pages = "23--27",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction

AU - Xie, Donghua

AU - Annex, Brian H.

AU - Donatucci, Craig F.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The past decade has seen an explosion of new information on the physiology of penile erection, and pathophysiology of erectile dysfunction (ED). Hypercholesterolemia is a chronic condition that can lead to degeneration in the vasculature bed and can result in ED if the penile vasculature is involved. Angiogenesis is the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth to treat disorders of inadequate tissue perfusion, such as coronary artery disease and ED. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future. Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm for the treatment of ischemic heart and/or peripheral vascular disease, though clinical studies have not achieved similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, novel therapies which target multiple different angiogenic pathways are also being developed and tested. The penis is a convenient tissue target for gene therapy because of its external location and accessibility, the ubiquity of endothelial lined spaces, and low level of blood flow, especially in the flaccid state. Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the development of growth factors for hypercholesterolemic ED, the use of various growth factors for ED therapy, their routes of delivery, and the results in animal studies.

AB - The past decade has seen an explosion of new information on the physiology of penile erection, and pathophysiology of erectile dysfunction (ED). Hypercholesterolemia is a chronic condition that can lead to degeneration in the vasculature bed and can result in ED if the penile vasculature is involved. Angiogenesis is the growth of new blood vessels from preexisting vasculature. Therapeutic angiogenesis seeks to harness the mechanisms of vascular growth to treat disorders of inadequate tissue perfusion, such as coronary artery disease and ED. There have been tremendous changes in the field of therapeutic angiogenesis over the past decade, and there is much promise for the future. Initial preclinical work with cytokine growth factor delivery resulted in a great deal of enthusiasm for the treatment of ischemic heart and/or peripheral vascular disease, though clinical studies have not achieved similar success. With an increased understanding of the complex mechanisms involved in angiogenesis, novel therapies which target multiple different angiogenic pathways are also being developed and tested. The penis is a convenient tissue target for gene therapy because of its external location and accessibility, the ubiquity of endothelial lined spaces, and low level of blood flow, especially in the flaccid state. Therapeutic angiogenesis is an exciting field that continues to evolve. This review will focus on the development of growth factors for hypercholesterolemic ED, the use of various growth factors for ED therapy, their routes of delivery, and the results in animal studies.

KW - Angiogenic growth factors

KW - Erectile dysfunction

KW - Hypercholesterolemia

KW - Nitric oxide synthase

UR - http://www.scopus.com/inward/record.url?scp=37749009768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37749009768&partnerID=8YFLogxK

U2 - 10.1111/j.1745-7262.2008.00372.x

DO - 10.1111/j.1745-7262.2008.00372.x

M3 - Review article

C2 - 18087640

AN - SCOPUS:37749009768

VL - 10

SP - 23

EP - 27

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 1

ER -